In Part 2, Hanna Svanbäck discusses the latest and most significant innovations in Alzheimer's care. She also considers whether healthcare systems are prepared for the anticipated surge in cases, and shares some positive news about prevention.
Speaker bio Hanna Svanbäck is the Executive Director for Neuroscience, Eli Lilly, overseeing operations in the UK, Ireland and the Nordic countries. Hanna has over 15 years of experience at Lilly and is proud to lead the Neurosciences function given Lilly's long-standing commitment to advancing scientific innovation in this field. Hanna's passion for science and her dedication to utilising innovative approaches to enhance patient care are underpinned by her academic studies in Engineering Genomics and Biotechnology from the University of Umeå, Sweden and University of Manchester.
EMJ GOLD: Pharma news, views and analysis